摘要:
A process for the industrial scale manufacture of 4-(4-fluorophenyl)-N-alkylnipecotinate esters by the addition of 4-fluorophenylmagnesium halide in tetrahydrofuran to 3,4-unsaturated-3-piperidine esters.
摘要:
Atorvastatin calcium propylene glycol solvates and processes to prepare these novel solvates which are particularly useful and suitable for pharmaceutical applications.
摘要:
A process for preparing (R)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-5-hydroxy-3-oxo-1-heptanoic acid, tert-butylester comprising: (a) reduction of 5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-3-oxo-1-pentanoic acid, (R)-2-hydroxy-1,2,2-triphenylethyl ester; (b) hydrolysis of (R)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-3-hydroxy-1-pentanoic acid, (R)-2-hydroxy-1,2,2-triphenylethyl ester using an alkali base in a solvent to form the acid; (c) alkylation of the acid forming (R)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-5-hydroxy-3-oxo-1-heptanoic acid, tert-butylester.
摘要:
Atorvastatin calcium propylene glycol solvates and processes to prepare these novel solvates which are particularly useful and suitable for pharmaceutical applications.
摘要:
Atorvastatin calcium propylene glycol solvates and processes to prepare these novel solvates which are particularly useful and suitable for pharmaceutical applications.
摘要:
Atorvastatin calcium propylene glycol solvates and processes to prepare these novel solvates which are particularly useful and suitable for pharmaceutical applications.
摘要:
The present invention discloses a method and an apparatus for notification of emitted energy. The method includes: performing an emitted energy decrease on resource elements in a current cell that have a same time-frequency location as part or all of resource elements where a reference signal of a neighboring cell is located; obtaining an emitted energy parameter of an energy non-decreased resource element (NRE) in the current cell according to a decreased amount of emitted energy of an emitted energy decreased resource element (DRE); and notifying the emitted energy parameter of the NRE to a user equipment (UE). According to embodiments of the present invention, the waste of emitted energy may be avoided, the emitted energy of part of REs is increased, and further, the signal to interference plus noise ratio (SINR) and throughput of service data may be increased.
摘要:
Embodiments of the present invention provide a method and an apparatus for performing channel measurement for a cell. The method includes: sending information about a location of a to-be-measured reference signal to a user equipment, where the location of the to-be-measured reference signal is a part of a location occupied by a reference signal of the cell; and receiving a channel measurement report of the cell. The channel measurement report is sent by the user equipment and is obtained after the user equipment performs channel measurement for the cell according to the information about the location of the to-be-measured reference signal.
摘要:
A method, a network device, and a system for determining resource mapping in CoMP transmission are disclosed. The method includes: the cooperative cells that perform CoMP transmission for a UE negotiate a mapping rule used by the cooperative cells when the status of the CoMP transmission of the UE changes, where the mapping rule includes the number of and position of OFDM symbols allocated to a PDCCH domain and/or a data channel domain; and the negotiated mapping rule is notified to the UE. In this embodiment, before the downlink signals are transmitted, the mapping rule used by each cooperative cell for CoMP transmission is negotiated between the cooperative cells, and therefore, the UE can accurately receive the signal sent by multiple cooperative cells and the performance of CoMP transmission in the system is improved.
摘要:
A process is provided for preparing (R)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-5-hydroxy-3-oxo-1-heptanoic acid, R-substituted ester 9 comprising: (a) reacting the aldehyde 1 with the enolate form of (S)-2-hydroxy-1,2,2-triphenylethyl acetate substituent in a chelating co-solvent; (b) hydrolysis of (R,S)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-3-hydroxy-1-pentanoic acid, (S)-2-hydroxy-1,2,2-triphenylethyl ester (2a and 2b) using a base, preferably an alkali metal base, preferably in a solvent to form the carboxylic acid 7; (c) treating the acid 7 with a chiral base to form a salt and purifying the salt to obtain enantiomerically enriched (R)-7 chiral base salt; (d) alkylation of the (R)-7 chiral base salt or the free base derived from (R)-7, forming (R)-5-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-yl]-5-hydroxy-3-oxo-1-heptanoic acid, R-substituted ester 9 and atorvastatin calcium 6, wherein R is a C1 to C6 alkyl, C6 to C9 aryl or C7 to C10 aralkyl.